Kalaris Therapeutics, Inc.
KLRS
$4.16
$0.081.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.86M | -10.00M | -11.89M | -11.35M | -10.20M |
| Total Depreciation and Amortization | 10.00K | 10.00K | 3.00K | -- | -- |
| Total Amortization of Deferred Charges | -- | 0.00 | 0.00 | 0.00 | 186.00K |
| Total Other Non-Cash Items | 402.00K | 58.00K | 567.00K | 591.00K | 223.00K |
| Change in Net Operating Assets | -1.14M | 2.87M | -9.00K | -1.78M | 2.35M |
| Cash from Operations | -11.58M | -7.06M | -11.33M | -12.54M | -7.44M |
| Capital Expenditure | -- | -17.00K | -183.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.35M | 15.00M | -34.52M | -- | -- |
| Cash from Investing | -50.35M | 14.98M | -34.71M | -- | -- |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 7.50M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.00K | 42.00M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.77M | 5.74M | 0.00 | 0.00 | 99.77M |
| Cash from Financing | -1.70M | 47.74M | 0.00 | 0.00 | 107.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.63M | 55.67M | -46.04M | -12.54M | 99.83M |